Day: February 24, 2026

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVID Full year 2026 revenue guidance of $810 million – $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpointWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026. Olivier Loeillot, President...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 – $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) — – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa...

Purpose Investments Inc. Announces Final February 2026 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund

Written by Customer Service on February 24, 2026. Posted in Dividend Reports And Estimates.

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final February 2026 distribution rates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts for the month of February. Ex-distribution date is February 25, 2026.Open-End Fund Ticker Symbol Final distribution per unit Record Date Payable Date Distribution FrequencyPurpose USD Cash Management Fund – ETF Units MNU.U US $ 0.2841 02/25/2026 03/03/2026 MonthlyPurpose Cash Management Fund – ETF Units MNY $ 0.1886 02/25/2026 03/03/2026 MonthlyPurpose High Interest Savings Fund – ETF Units PSA $ 0.0819 02/25/2026 03/03/2026 MonthlyPurpose US Cash Fund – ETF Units PSU.U US $ 0.2699 02/25/2026 03/03/2026 Monthly About...

Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 2024 2025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis 2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024 Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basisCLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,...

First Watch Restaurant Group, Inc. Reports 2025 Financial Results and Provides Outlook for 2026

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

Total revenues increased 20.3% to $1.2 billion, with System-wide sales up 16.1% to $1.4 billion Income from operations margin of 2.3% and Restaurant level operating profit margin of 18.5% Net income of $19.4 million and Adjusted EBITDA of $120.9 million 64 system-wide restaurants opened across 23 statesBRADENTON, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 28, 2025 (“Q4 2025”) and the 52-week fiscal year ended December 28, 2025 (“2025”) compared to the thirteen weeks ended December 29, 2024 (“Q4 2024”) and the 52-week fiscal year ended December 29, 2024 (“2024”) and provided an outlook for the 52-week fiscal...

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial ResultsFourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue.Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the fourth quarter of 2024, and down from 76.6% in the third quarter of 2025.Gross margin reflects one-time costs of approximately $1.9 million, or 3% for the fourth quarter of 2025, related to the U.S. Food and Drug Administration (“FDA”)...

Enviri Corporation Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter revenues totaled $556 million Fourth quarter GAAP consolidated loss from continuing operations of $86 million, including expenses related to the pending sale of Clean Earth and spin-off of Harsco Environmental and Harsco Rail as well as certain contract adjustments in Harsco Rail Adjusted EBITDA in Q4 totaled $70 million Full year 2025 revenue totaled $2.2 billion; GAAP consolidated loss from continuing operations was $160 million; and Adjusted EBITDA totaled $275 million 2026 outlook: Adjusted EBITDA for Harsco Environmental and Harsco Rail (“New Enviri”) expected to be modestly below 2025 at guidance mid-point, as improvement in Harsco Environmental to be offset by Harsco RailPHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) (the “Company”) today reported...

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2025 financial results, business achievements and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivered approximately 30 percent quarterly revenue growth and achieved our 2025 guidance range in the first...

Shoals Technologies Group, Inc. Reports Financial Results for Fourth Quarter 2025

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

– Record Quarterly Revenue of $148.3 million – – Quarterly Operating Profit of $17.4 million – – Quarterly Net Income of $8.1 million – – Quarterly Adjusted EBITDA1 of $30.3 million – – Record Backlog and Awarded Orders of $747.6 million – – Provides First Quarter and Full Year 2026 Outlook – PORTLAND, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components, including battery energy storage solutions (“BESS”), and Original Equipment Manufacturer (“OEM”) components for the global energy transition market, today announced results for its fourth quarter ended December 31, 2025. “2025 was an exceptional year for Shoals. While the rapidly shifting political climate brought some volatility,...

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on February 24, 2026. Posted in Earnings Releases And Operating Results.

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN),...

Day: February 24, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals